Retina (Philadelphia, Pa.) · 2025
OUTCOMES OF CRYOTHERAPY FOR THE TREATMENT OF RETINOBLASTOMA IN 92 CONSECUTIVE PATIENTS.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Younghoon, Negretti Guy S, Westcott Mark, Sagoo Mandeep S, Reddy M Ashwin
Аннотация
PURPOSE: To report the incidence, risk factors, clinical course, and visual outcomes of rhegmatogenous retinal detachment (RRD) and vitreous haemorrhage (VH) following cryotherapy for retinoblastoma.
METHODS: A single-centre retrospective review of patients treated with cryotherapy for retinoblastoma between January 2013 and December 2022.
RESULTS: Of 124 eyes in 92 patients treated with cryotherapy, RRD developed in 7 (6%) and VH in 9 (7%) eyes. RRD persisted in 1 eye (<1%) and VH in 5 eyes (4%), while RRD and VH resolved spontaneously in remaining eyes. Increased cryotherapy applications were associated with VH risk (p<0.01) but not with RRD. Cryotherapy recipients who had also received intra-arterial chemotherapy (n=50) were associated with VH risk (p=0.01). Management for persistent complications were referral for scleral buckling (1 RRD), observation (1 VH), or enucleation (4 VH: 3 tumour progression, 1 no retinal view). Cryotherapy-induced visual loss occurred in one RRD (<1%, baseline vs final visual acuity: 20/20 vs 20/40), and in one VH (<1%, enucleation due to no view). Baseline vision was preserved in the majority of globe-salvaged cases.
CONCLUSION: Complications post-cryotherapy in retinoblastoma management are rare. Increased cryotherapy applications may increase the risk of VH, but cryotherapy-related visual loss was rare.
METHODS: A single-centre retrospective review of patients treated with cryotherapy for retinoblastoma between January 2013 and December 2022.
RESULTS: Of 124 eyes in 92 patients treated with cryotherapy, RRD developed in 7 (6%) and VH in 9 (7%) eyes. RRD persisted in 1 eye (<1%) and VH in 5 eyes (4%), while RRD and VH resolved spontaneously in remaining eyes. Increased cryotherapy applications were associated with VH risk (p<0.01) but not with RRD. Cryotherapy recipients who had also received intra-arterial chemotherapy (n=50) were associated with VH risk (p=0.01). Management for persistent complications were referral for scleral buckling (1 RRD), observation (1 VH), or enucleation (4 VH: 3 tumour progression, 1 no retinal view). Cryotherapy-induced visual loss occurred in one RRD (<1%, baseline vs final visual acuity: 20/20 vs 20/40), and in one VH (<1%, enucleation due to no view). Baseline vision was preserved in the majority of globe-salvaged cases.
CONCLUSION: Complications post-cryotherapy in retinoblastoma management are rare. Increased cryotherapy applications may increase the risk of VH, but cryotherapy-related visual loss was rare.